Follow the people · Insider
Brian Adams
Brian Adams files insider transactions with the SEC as a chief legal officer of Kymera Therapeutics (KYMR). We hold 1 disclosed purchase or sale filed since 17 April 2015, 1 of them in the last 90 days.
- Files forKYMR
- Disclosed buys and sells1 in all, 1 in the last 90 days
- Last disclosure4 September 2026
Positions held
3 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 3 September 2025 — 4 September 2026Chief Legal Officer · Kymera Therapeutics (KYMR)9 Form 4 lines · source: SEC Form 4
- Filed 20 July 2020 — 29 July 2025Chief Legal Officer · Relay Therapeutics (RLAY)63 Form 4 lines · source: SEC Form 4
- Filed 15 April 2015 — 15 February 2018General Counsel and Secretary · Keryx Biopharmaceuticals (KERX)30 Form 4 lines · source: SEC Form 4
Everything they disclosed
102 entries, newest first — one per disclosure report, one per Form 4 line- ▼ sold on the open market 1,209 shares of Kymera TherapeuticsSEC Form 44 September 2026Common Stock · traded 4 September 2026 · filed 4 September 2026
- ▼ sold on the open market 3,025 shares of Kymera TherapeuticsSEC Form 44 September 2026Common Stock · traded 4 September 2026 · filed 4 September 2026
- ▼ sold on the open market 2,137 shares of Kymera TherapeuticsSEC Form 44 September 2026Common Stock · traded 4 September 2026 · filed 4 September 2026
- was granted 4,125 shares of Kymera TherapeuticsSEC Form 44 March 2026Common Stock · traded 2 March 2026 · filed 4 March 2026
- was granted 8,250 shares of Kymera Therapeutics (a derivative holding)SEC Form 44 March 2026Stock Option (Right to Buy) · traded 2 March 2026 · filed 4 March 2026
- was granted 8,250 shares of Kymera Therapeutics (a derivative holding)SEC Form 44 March 2026Stock Option (Right to Buy) · traded 2 March 2026 · filed 4 March 2026
- was granted 4,125 shares of Kymera TherapeuticsSEC Form 44 March 2026Common Stock · traded 2 March 2026 · filed 4 March 2026
- was granted 105,000 shares of Kymera Therapeutics (a derivative holding)SEC Form 43 September 2025Stock Option (Right to Buy) · traded 3 September 2025 · filed 3 September 2025
- was granted 52,500 shares of Kymera TherapeuticsSEC Form 43 September 2025Common Stock · traded 3 September 2025 · filed 3 September 2025
- ▼ sold on the open market 1,637 shares of Relay TherapeuticsSEC Form 430 July 2025Common Stock · traded 28 July 2025 · filed 30 July 2025
- ▼ sold on the open market 18,276 shares of Relay TherapeuticsSEC Form 430 July 2025Common Stock · traded 29 July 2025 · filed 30 July 2025
- ▼ sold on the open market 1,644 shares of Relay TherapeuticsSEC Form 430 April 2025Common Stock · traded 28 April 2025 · filed 30 April 2025
- ▼ sold on the open market 12,943 shares of Relay TherapeuticsSEC Form 430 April 2025Common Stock · traded 30 April 2025 · filed 30 April 2025
- ▼ sold on the open market 298 shares of Relay TherapeuticsSEC Form 431 March 2025Common Stock · traded 27 March 2025 · filed 31 March 2025
- ▼ sold on the open market 33,688 shares of Relay TherapeuticsSEC Form 430 January 2025Common Stock · traded 28 January 2025 · filed 30 January 2025
- was granted 139,141 shares of Relay TherapeuticsSEC Form 430 January 2025Common Stock · traded 28 January 2025 · filed 30 January 2025
- ▼ sold on the open market 20,791 shares of Relay TherapeuticsSEC Form 430 January 2025Common Stock · traded 30 January 2025 · filed 30 January 2025
- was granted 275,000 shares of Relay Therapeutics (a derivative holding)SEC Form 414 January 2025Stock Option (Right to Buy) · traded 10 January 2025 · filed 14 January 2025
- ▼ sold on the open market 299 shares of Relay TherapeuticsSEC Form 431 December 2024Common Stock · traded 27 December 2024 · filed 31 December 2024
- ▼ sold on the open market 1,632 shares of Relay TherapeuticsSEC Form 430 October 2024Common Stock · traded 28 October 2024 · filed 30 October 2024
- ▼ sold on the open market 295 shares of Relay TherapeuticsSEC Form 41 October 2024Common Stock · traded 27 September 2024 · filed 1 October 2024
- ▼ sold on the open market 1,638 shares of Relay TherapeuticsSEC Form 431 July 2024Common Stock · traded 29 July 2024 · filed 31 July 2024
- ▼ sold on the open market 295 shares of Relay TherapeuticsSEC Form 41 July 2024Common Stock · traded 27 June 2024 · filed 1 July 2024
- ▼ sold on the open market 1,623 shares of Relay TherapeuticsSEC Form 429 April 2024Common Stock · traded 29 April 2024 · filed 29 April 2024
- ▼ sold on the open market 348 shares of Relay TherapeuticsSEC Form 429 March 2024Common Stock · traded 27 March 2024 · filed 29 March 2024
- ▼ sold on the open market 1,929 shares of Relay TherapeuticsSEC Form 431 January 2024Common Stock · traded 29 January 2024 · filed 31 January 2024
- was granted 200,000 shares of Relay TherapeuticsSEC Form 418 January 2024Common Stock · traded 16 January 2024 · filed 18 January 2024
- ▼ sold on the open market 294 shares of Relay TherapeuticsSEC Form 429 December 2023Common Stock · traded 27 December 2023 · filed 29 December 2023
- ▼ sold on the open market 1,632 shares of Relay TherapeuticsSEC Form 41 November 2023Common Stock · traded 30 October 2023 · filed 1 November 2023
- ▼ sold on the open market 294 shares of Relay TherapeuticsSEC Form 429 September 2023Common Stock · traded 27 September 2023 · filed 29 September 2023
- ▼ sold on the open market 1,628 shares of Relay TherapeuticsSEC Form 431 July 2023Common Stock · traded 28 July 2023 · filed 31 July 2023
- ▼ sold on the open market 294 shares of Relay TherapeuticsSEC Form 428 June 2023Common Stock · traded 27 June 2023 · filed 28 June 2023
- ▼ sold on the open market 1,936 shares of Relay TherapeuticsSEC Form 41 June 2023Common Stock · traded 28 April 2023 · filed 1 June 2023
- ▼ sold on the open market 863 shares of Relay TherapeuticsSEC Form 41 May 2023Common Stock · traded 28 April 2023 · filed 1 May 2023
- ▼ sold on the open market 347 shares of Relay TherapeuticsSEC Form 428 March 2023Common Stock · traded 27 March 2023 · filed 28 March 2023
- ▼ sold on the open market 864 shares of Relay TherapeuticsSEC Form 431 January 2023Common Stock · traded 30 January 2023 · filed 31 January 2023
- was granted 97,630 shares of Relay Therapeutics (a derivative holding)SEC Form 419 January 2023Stock Option (Right to Buy) · traded 17 January 2023 · filed 19 January 2023
- was granted 73,220 shares of Relay Therapeutics (a derivative holding)SEC Form 419 January 2023Stock Option (Right to Buy) · traded 17 January 2023 · filed 19 January 2023
- was granted 85,425 shares of Relay TherapeuticsSEC Form 419 January 2023Common Stock · traded 17 January 2023 · filed 19 January 2023
- ▼ sold on the open market 9,994 shares of Relay TherapeuticsSEC Form 413 January 2023Common Stock · traded 12 January 2023 · filed 13 January 2023
- ▼ sold on the open market 295 shares of Relay TherapeuticsSEC Form 428 December 2022Common Stock · traded 27 December 2022 · filed 28 December 2022
- ▼ sold on the open market 728 shares of Relay TherapeuticsSEC Form 41 November 2022Common Stock · traded 28 October 2022 · filed 1 November 2022
- ▼ sold on the open market 294 shares of Relay TherapeuticsSEC Form 429 September 2022Common Stock · traded 27 September 2022 · filed 29 September 2022
- ▼ sold on the open market 734 shares of Relay TherapeuticsSEC Form 429 July 2022Common Stock · traded 28 July 2022 · filed 29 July 2022
- ▼ sold on the open market 300 shares of Relay TherapeuticsSEC Form 428 June 2022Common Stock · traded 27 June 2022 · filed 28 June 2022
- ▼ sold on the open market 708 shares of Relay TherapeuticsSEC Form 42 May 2022Common Stock · traded 28 April 2022 · filed 2 May 2022
- ▼ sold on the open market 333 shares of Relay TherapeuticsSEC Form 431 March 2022Common Stock · traded 29 March 2022 · filed 31 March 2022
- was granted 78,540 shares of Relay Therapeutics (a derivative holding)SEC Form 431 January 2022Stock Option (Right to Buy) · traded 27 January 2022 · filed 31 January 2022
- was granted 39,270 shares of Relay TherapeuticsSEC Form 431 January 2022Common Stock · traded 27 January 2022 · filed 31 January 2022
- was granted 658 shares of Relay TherapeuticsSEC Form 47 January 2022Common Stock · traded 31 December 2021 · filed 7 January 2022
- ▼ sold on the open market 295 shares of Relay TherapeuticsSEC Form 427 December 2021Common Stock · traded 27 December 2021 · filed 27 December 2021
- exercised options over 6,500 shares of Relay Therapeutics (a derivative holding)SEC Form 416 November 2021Stock Option (Right to Buy) · traded 15 November 2021 · filed 16 November 2021
- exercised options over 6,500 shares of Relay TherapeuticsSEC Form 416 November 2021Common Stock · traded 15 November 2021 · filed 16 November 2021
- ▼ sold on the open market 6,500 shares of Relay TherapeuticsSEC Form 416 November 2021Common Stock · traded 15 November 2021 · filed 16 November 2021
- ▼ sold on the open market 293 shares of Relay TherapeuticsSEC Form 427 September 2021Common Stock · traded 27 September 2021 · filed 27 September 2021
- exercised options over 6,500 shares of Relay Therapeutics (a derivative holding)SEC Form 413 September 2021Stock Option (Right to Buy) · traded 13 September 2021 · filed 13 September 2021
- exercised options over 6,500 shares of Relay TherapeuticsSEC Form 413 September 2021Common Stock · traded 13 September 2021 · filed 13 September 2021
- ▼ sold on the open market 6,500 shares of Relay TherapeuticsSEC Form 413 September 2021Common Stock · traded 13 September 2021 · filed 13 September 2021
- ▼ sold on the open market 293 shares of Relay TherapeuticsSEC Form 430 June 2021Common Stock · traded 28 June 2021 · filed 30 June 2021
- exercised options over 6,500 shares of Relay TherapeuticsSEC Form 49 June 2021Common Stock · traded 7 June 2021 · filed 9 June 2021
- ▼ sold on the open market 6,500 shares of Relay TherapeuticsSEC Form 49 June 2021Common Stock · traded 7 June 2021 · filed 9 June 2021
- exercised options over 6,500 shares of Relay Therapeutics (a derivative holding)SEC Form 49 June 2021Stock Option (Right to Buy) · traded 7 June 2021 · filed 9 June 2021
- exercised options over 6,500 shares of Relay TherapeuticsSEC Form 428 April 2021Common Stock · traded 26 April 2021 · filed 28 April 2021
- ▼ sold on the open market 6,500 shares of Relay TherapeuticsSEC Form 428 April 2021Common Stock · traded 26 April 2021 · filed 28 April 2021
- exercised options over 6,500 shares of Relay Therapeutics (a derivative holding)SEC Form 428 April 2021Stock Option (Right to Buy) · traded 26 April 2021 · filed 28 April 2021
- was granted 31,740 shares of Relay Therapeutics (a derivative holding)SEC Form 426 March 2021Stock Option (Right to Buy) · traded 26 March 2021 · filed 26 March 2021
- was granted 15,870 shares of Relay TherapeuticsSEC Form 426 March 2021Common Stock · traded 26 March 2021 · filed 26 March 2021
- exercised options over 5,000 shares of Relay TherapeuticsSEC Form 429 January 2021Common Stock · traded 28 January 2021 · filed 29 January 2021
- ▼ sold on the open market 5,000 shares of Relay TherapeuticsSEC Form 429 January 2021Common Stock · traded 28 January 2021 · filed 29 January 2021
- exercised options over 5,000 shares of Relay Therapeutics (a derivative holding)SEC Form 429 January 2021Stock Option (Right to Buy) · traded 28 January 2021 · filed 29 January 2021
- was granted 67,588 shares of Relay Therapeutics (a derivative holding)SEC Form 415 December 2020Stock Option (Right to Buy) · traded 11 December 2020 · filed 15 December 2020
- ▲ bought on the open market 10,000 shares of Relay TherapeuticsSEC Form 421 July 2020Common Stock · traded 20 July 2020 · filed 21 July 2020
- ▼ sold on the open market 5,652 shares of Keryx BiopharmaceuticalsSEC Form 416 February 2018Common Stock · traded 15 February 2018 · filed 16 February 2018
- ▼ sold on the open market 1,541 shares of Keryx BiopharmaceuticalsSEC Form 431 January 2018Common Stock · traded 29 January 2018 · filed 31 January 2018
- ▼ sold on the open market 753 shares of Keryx BiopharmaceuticalsSEC Form 48 January 2018Common Stock · traded 5 January 2018 · filed 8 January 2018
- ▼ sold on the open market 1,405 shares of Keryx BiopharmaceuticalsSEC Form 431 October 2017Common Stock · traded 30 October 2017 · filed 31 October 2017
- ▼ sold on the open market 630 shares of Keryx BiopharmaceuticalsSEC Form 46 October 2017Common Stock · traded 5 October 2017 · filed 6 October 2017
- ▼ sold on the open market 1,445 shares of Keryx BiopharmaceuticalsSEC Form 41 August 2017Common Stock · traded 31 July 2017 · filed 1 August 2017
- ▼ sold on the open market 641 shares of Keryx BiopharmaceuticalsSEC Form 46 July 2017Common Stock · traded 5 July 2017 · filed 6 July 2017
- ▼ sold on the open market 1,441 shares of Keryx BiopharmaceuticalsSEC Form 43 May 2017Common Stock · traded 1 May 2017 · filed 3 May 2017
- ▼ sold on the open market 1,090 shares of Keryx BiopharmaceuticalsSEC Form 418 April 2017Common Stock · traded 17 April 2017 · filed 18 April 2017
- ▼ sold on the open market 642 shares of Keryx BiopharmaceuticalsSEC Form 46 April 2017Common Stock · traded 5 April 2017 · filed 6 April 2017
- was granted 48,750 shares of Keryx BiopharmaceuticalsSEC Form 415 March 2017Common Stock · traded 14 February 2017 · filed 15 March 2017
- was granted 97,500 shares of Keryx Biopharmaceuticals (a derivative holding)SEC Form 415 March 2017Employee Stock Option (Right to Buy) · traded 14 February 2017 · filed 15 March 2017
- ▼ sold on the open market 6,984 shares of Keryx BiopharmaceuticalsSEC Form 431 January 2017Common Stock · traded 30 January 2017 · filed 31 January 2017
- ▼ sold on the open market 1,265 shares of Keryx BiopharmaceuticalsSEC Form 418 January 2017Common Stock · traded 17 January 2017 · filed 18 January 2017
- ▼ sold on the open market 759 shares of Keryx BiopharmaceuticalsSEC Form 46 January 2017Common Stock · traded 5 January 2017 · filed 6 January 2017
- ▼ sold on the open market 1,106 shares of Keryx BiopharmaceuticalsSEC Form 418 October 2016Common Stock · traded 17 October 2016 · filed 18 October 2016
- ▼ sold on the open market 647 shares of Keryx BiopharmaceuticalsSEC Form 46 October 2016Common Stock · traded 5 October 2016 · filed 6 October 2016
- ▼ sold on the open market 1,083 shares of Keryx BiopharmaceuticalsSEC Form 418 July 2016Common Stock · traded 15 July 2016 · filed 18 July 2016
- ▼ sold on the open market 660 shares of Keryx BiopharmaceuticalsSEC Form 46 July 2016Common Stock · traded 5 July 2016 · filed 6 July 2016
- ▼ sold on the open market 1,060 shares of Keryx BiopharmaceuticalsSEC Form 418 April 2016Common Stock · traded 15 April 2016 · filed 18 April 2016
- ▼ sold on the open market 759 shares of Keryx BiopharmaceuticalsSEC Form 47 April 2016Common Stock · traded 5 April 2016 · filed 7 April 2016
- was granted 53,750 shares of Keryx BiopharmaceuticalsSEC Form 41 February 2016Common Stock · traded 28 January 2016 · filed 1 February 2016
- was granted 107,500 shares of Keryx Biopharmaceuticals (a derivative holding)SEC Form 41 February 2016Employee Stock Option (Right to Buy) · traded 28 January 2016 · filed 1 February 2016
- ▼ sold on the open market 1,322 shares of Keryx BiopharmaceuticalsSEC Form 420 January 2016Common Stock · traded 15 January 2016 · filed 20 January 2016
- ▼ sold on the open market 3,003 shares of Keryx BiopharmaceuticalsSEC Form 48 January 2016Common Stock · traded 5 January 2016 · filed 8 January 2016
- ▼ sold on the open market 1 share of Keryx BiopharmaceuticalsSEC Form 48 January 2016Common Stock · traded 6 January 2016 · filed 8 January 2016
- ▼ sold on the open market 3,004 shares of Keryx BiopharmaceuticalsSEC Form 46 January 2016Common Stock · traded 6 January 2016 · filed 6 January 2016
- ▼ sold on the open market 1,011 shares of Keryx BiopharmaceuticalsSEC Form 419 October 2015Common Stock · traded 15 October 2015 · filed 19 October 2015
- ▼ sold on the open market 1,086 shares of Keryx BiopharmaceuticalsSEC Form 417 July 2015Common Stock · traded 15 July 2015 · filed 17 July 2015
- ▼ sold on the open market 4,320 shares of Keryx BiopharmaceuticalsSEC Form 417 April 2015Common Stock · traded 15 April 2015 · filed 17 April 2015
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.